GlaxoSmithKline plc / ID Biomedical Corporation

Seasonal Influenza (Vaccine Prevention)

Disease Overview

Seasonal influenza causes substantial annual morbidity and mortality globally; vaccine supply has historically been constrained by limited egg-based manufacturing capacity. The 2004-2005 Chiron contamination crisis in Liverpool exposed acute US vulnerability and created an opening for new flu vaccine entrants.

Competitive Landscape

At the time of the 2005 deal, the US flu vaccine market was dominated by Sanofi Pasteur's Fluzone, with Chiron's Fluvirin (recovering from 2004 license suspension), MedImmune's FluMist (live attenuated nasal), and GSK's own Fluarix (FDA-approved 2005). ID Biomedical's Fluviral, marketed in Canada since 2001 and supplying ~75% of Canadian demand, was on FDA fast-track for US licensure as FluLaval (approved October 2006 per CIDRAP). The acquisition gave GSK a second US-licensed flu vaccine plus a Canadian high-containment H5N1 pandemic facility supporting Canadian government pandemic-preparedness contracts. Combined with the Dresden facility, GSK projected ~150M doses/year capacity by decade's end - positioning it alongside Sanofi as a top-two global flu vaccine supplier. The deal also brought an intranasal flu vaccine candidate (FluINsure) and Streptococcal vaccine programs, broadening GSK's vaccines portfolio beyond Corixa-acquired adjuvants.